Therma Bright Inc.

Established in Toronto, Canada, in 2001 as The Jenex Corporation before rebranding to Therma Bright Inc. in February 2018, Therma Bright Inc. specializes in creating and distributing various medical and consumer health products. Their diverse offerings include rapid COVID-19 diagnostic tests like AcuVid, which screens for both antigens and antibodies. For pain relief, they provide devices such as Benepod, a hot and cold contrast therapy system designed to manage discomfort without medication. The company also addresses circulatory issues with Venowave, a medical compression pump aimed at mitigating symptoms associated with poor circulation. Furthermore, Therma Bright caters to the cosmeceutical industry with products like InterceptCS, a cold sore prevention system utilizing safe, controlled topical heat, and TherOZap, a thermal device that alleviates the pain, itching, and inflammation from insect bites and stings by reducing the inflammatory response. Their clientele spans both individual consumers and healthcare practitioners.

Therma Bright Inc. trades as THRM.V on TSXV. The company is classified in Healthcare / Medical - Devices and reports in CAD.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $80,269 of revenue and -$4.34M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Therma Bright Inc. can be compared against peers such as Appili Therapeutics Inc., Aptose Biosciences Inc., Avricore Health Inc., CordovaCann Corp., Mountain Valley MD Holdings Inc., Revive Therapeutics Ltd..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $3.19M, beta of 1.11, and return on equity of +277.3%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

THRM.V currently shows total debt of $40,000 and beta of 1.11. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.thermabright.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.